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Abstract: Objective To determine whether naturally occurring autoantibodies against the prion protein
are present in individuals with genetic prion disease mutations and controls, and if so, whether they are
protective against prion disease. Methods In this case–control study, we collected 124 blood samples from
individuals with a variety of pathogenic PRNP mutations and 78 control individuals with a positive family
history of genetic prion disease but lacking disease-associated PRNP mutations. Antibody reactivity was
measured using an indirect ELISA for the detection of human immunoglobulin G1–4 antibodies against
wild-type human prion protein. Multivariate linear regression models were constructed to analyze differ-
ences in autoantibody reactivity between (1) PRNP mutation carriers vs controls and (2) asymptomatic
vs symptomatic PRNP mutation carriers. Robustness of results was examined in matched cohorts. Re-
sults We found that antibody reactivity was present in a subset of both PRNP mutation carriers and
controls. Autoantibody levels were not influenced by PRNP mutation status or clinical manifestation of
prion disease. Post hoc analyses showed anti-PrPC autoantibody titers to be independent of personal
history of autoimmune disease and other immunologic disorders, as well as PRNP codon 129 polymor-
phism. Conclusions Pathogenic PRNP variants do not notably stimulate antibody-mediated anti-PrPC
immunity. Anti-PrPC immunoglobulin G autoantibodies are not associated with the onset of prion dis-
ease. The presence of anti-PrPC autoantibodies in the general population without any disease-specific
association suggests that relatively high titers of naturally occurring antibodies are well-tolerated.
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Structured abstract 
Objective. To determine whether naturally occurring autoantibodies against the prion protein 
are present in individuals with genetic prion disease mutations and controls, and if so, whether 
they are protective against prion disease.  
Methods. In this case-control study, we collected 124 blood samples from individuals with a 
variety of pathogenic PRNP mutations and 78 control individuals with a positive family history 
of genetic prion disease but lacking disease-associated PRNP mutations. Antibody reactivity 
was measured using an indirect ELISA for the detection of human IgG1-4 antibodies against 
wild-type human prion protein. Multivariate linear regression models were constructed to 
analyze differences in autoantibody reactivity between a) PRNP mutation carriers versus 
controls and b) asymptomatic versus symptomatic PRNP mutation carriers. Robustness of 
results was examined in matched cohorts. 
Results. We found that antibody reactivity was present in a subset of both PRNP mutation 
carriers and controls. Autoantibody levels were not influenced by PRNP mutation status nor 
clinical manifestation of prion disease. Post hoc analyses showed anti-PrPC autoantibody titers 
to be independent of personal history of autoimmune disease and other immunological 
disorders, as well as PRNP codon 129 polymorphism.  
Conclusions. Pathogenic PRNP variants do not notably stimulate antibody-mediated anti-PrPC 
immunity. Anti-PrPC IgG autoantibodies are not associated with the onset of prion disease. 
The presence of anti-PrPC autoantibodies in the general population without any disease-
specific association suggests that relatively high titers of naturally occurring antibodies are 
well tolerated. Clinicaltrials.gov identifier NCT02837705.  
  
Introduction 
Prion diseases are diseases of the central nervous system which not only occur as sporadic 
and transmissible forms, but can also be transmitted through the germ line as autosomal 
dominant traits 1. Genetic prion diseases (gPrDs) account for ~ 10-15 % of all prion diseases 
and are characterized by pathogenic, non-synonymous mutations of the human prion protein 
gene PRNP 2. The most prevalent human prion disease, sporadic Creutzfeldt-Jakob disease 
(sCJD), is characterized by a rapidly progressive dementia and a short survival time (usually 
< 1 year) from clinical onset 3. In contrast, PRNP mutation carriers often present with atypical 
phenotypes, e.g. long survival rates can be observed in Gerstmann-Sträussler-Scheinker 
disease (GSS) 4. 
The cellular prion protein PrPC consists of an unstructured, flexible tail (FT) on its N-terminal 
end and a C-terminal globular domain (GD) 5. We have shown in 2001 that humoral immunity 
against PrPC can protect against prion neuroinvasion 6. Antibodies against the FT of PrPC, or 
removal of amino acid residues from the FT, abrogate the neurotoxic effects of anti-PrPC-GD 
antibodies and reduce the toxicity of bona fide prions 7, 8. Naturally occurring PrP antibodies 
may exist in the general population: for instance, reactivity against a 21-residue PrP peptide 
was observed in commercial pooled immunoglobulin 9, and a unique blood group has been 
observed in individuals homozygous for the E219K polymorphism 10.  
Clinical trials have yet to deliver an effective anti-prion agent so far 11-14. An ongoing clinical 
study involves the administration of PRN100, a humanized antibody against PrPC-GD, to 
individuals suffering from CJD 15. While there is much hope that this trial will be successful, 
the murine counter-part of PRN100, ICSM18, exhibits an on-target, dose-dependent toxicity, 
and whether a therapeutic window exists has not yet been established 16-18.  
The frequency of PRNP missense variants exceeds the reported genetic prion disease 
prevalence, suggesting a spectrum of disease penetrance in gPrDs rather than complete 
penetrance of non-synonymous PRNP mutations 19. The mechanisms by which these 
mutations induce disease are still largely unclear. The majority of structural studies on human 
PrPC variants linked to genetic prion disease failed to identify consistent effects on global 
protein stability 20. Age of onset in gPrD is highly variable, and typically middle age or older, 
which might suggest that a protective mechanism guards some individuals against the prion 
protein-induced toxicity 2. We hypothesized that subtle conformational alterations of 
pathogenic PrPC variants could stochastically generate immunogenic neo-epitopes, which in 
turn might elicit a protective humoral anti-PrPC immune response. We therefore conducted an 
extensive search for such autoantibodies in individuals carrying pathogenic PRNP mutations, 
and in unaffected relatives as controls.  
  
Material and Methods 
Ethics statement. The Cantonal Ethics Committee of the Canton of Zurich approved this 
study (permit no. “KEK-ZH Nr.2015-0514”). This trial was registered at clinicaltrials.gov (no. 
NCT02837705). The protocol for this study was approved by the institutional review board at 
each participating institution with the University of Zurich being the lead regulatory site. Written 
informed patient consent was received by all individuals participating in this study.  
Human subjects and study design. We defined PRNP mutation carriers as individuals with 
a non-synonymous mutation in the open reading frame of the PRNP gene that was previously 
reported to be pathogenic 2. Between September 2015 and October 2018, we contacted both 
international patient organizations as well as national prion disease reference centers for 
further re-use of existing blood samples. Individuals at any age with a confirmed PRNP 
mutation were considered eligible for this study. Individuals with a confirmed PRNP mutation 
in a blood relative who did not undergo PRNP sequencing prior to enrollment in this study 
were also considered eligible if they gave consent for PRNP sequencing. Blood samples 
without information on age or gender were excluded from further analysis. PRNP wild-type 
individuals with neurological or psychiatric symptoms indicative of genetic prion disease were 
excluded from the study 21. Clinical manifestation of gPrD was defined as presence of both a 
pathogenic PRNP mutation and PrD-typical symptoms 21. The latter were assessed by clinical 
exam and neuropsychological assessment, in some cases complemented by ancillary tests 
such as presence of 14-3-3 proteins in cerebrospinal fluid, real-time quaking-induced 
conversion (RT-QuIC) assays, electroencephalography and magnetic resonance imaging 22. 
Personal history of autoimmune disease and other immunological disorders could be obtained 
in n = 141 of participants.  A detailed description of the patient cohort is given in Table 1. For 
sensitivity analysis, cases and controls were matched on age (± 5 years), gender and blood 
sample type (i.e. serum or plasma). 
PRNP genotyping. PRNP genotyping was performed using a modified version of the DNeasy 
Blood & Tissue Kit (Qiagen). 20 μL of PK (600 mAU/ml) and 200 μL of 5 M guanidine 
hydrochloride (GdnHCl) with 1% Triton-X100 at pH = 5.0 were added to 200 μL of 
anticoagulated blood, vortexed thoroughly and incubated for 24 h at room temperature. 200 
μL EtOH (96-100%) were added to the reaction and the rest of the DNA purification was 
performed according to the manufacturer’s guidelines. The primer pair PRNP_up and 
PRNP_low (Table e-1) was used in combination with Q5 high-fidelity DNA polymerase (New 
England Biolabs) to amplify the open reading frame from exon 2 of PRNP. Sanger sequencing 
was performed at the Department of Molecular Pathology (Institute of Surgical Pathology, 
University Hospital Zurich) using four different sequencing primers (PRNP_up, PRNP_up2, 
PRNP_low, PRNP_low2, Table e-1). Sequencing traces were aligned to reference DNA from 
the Reference Sequence (RefSeq) Database (O'Leary et al. 2016) using CLC Main 
Workbench (Qiagen) and packages sangerseqr23 and DECIPHER24 for Bioconductor25 in R. 
Statistical analyses. We performed a priori testing of anti-PrPC autoantibody reactivity for the 
following hypotheses: a) differences in anti-PrPC autoantibody reactivity between PRNP 
mutation carriers and PRNP wild-type individuals and b) differences in anti-PrPC autoantibody 
reactivity between PRNP mutation carriers showing clinical signs of prion diseases and those 
without. All other analyses were performed post hoc. We used already established predictors 
of autoimmune disease such as age 26 and gender 27 as well as storage conditions known to 
affect antibody responses such as presence of coagulation factors 28 as covariates in our 
multivariate regression model. Using the purposeful selection of covariates method as 
described previously 29, effects of covariates on autoantibody titers were tested by bivariate 
linear regression analyses using the Wald test and included for multivariate testing at a p-
value cut-off point of 0.25. In the multivariate model covariates were removed if they were non-
significant at the 0.1 alpha level or not a confounder, as determined by a change in the 
remaining parameter estimate greater than 20 % as compared to the full model. PRNP 
mutation status, clinical signs of prion disease, PRNP codon 129 polymorphism were added 
after establishment of significant confounders.  In matched cohorts, multivariate models were 
adjusted for matching factors.  
All values are given as average ± standard deviation unless mentioned otherwise. For 
analysis, autoantibody titers were log10-transformed, and reported β coefficients and 
confidence intervals represent back-transformed values. Normality was tested using the 
D’Agostino-Pearson normality test. For values following a Gaussian distribution, differences 
between two groups were compared using two-tailed student’s T test. For not normally 
distributed values, Mann Whitney U Test was used for comparison of two groups. For 
comparison of categorical variables, Fisher’s exact test and chi-squared test were used for  
comparison of two and more than two groups, respectively. Pearson correlation coefficient 
was computed for data sampled from Gaussian distributions and Spearman's rho for those 
sampled from non-Gaussian distributions. Matching of cases and controls was done using the 
find.matches function from the Hmisc package in R. We used lm for R for linear regression 
analysis. Python and R were used for statistical analysis, data visualization was performed 
using Prism 7 (GraphPad).  
Data availability statement. The study participants, if they have not undergone predictive 
testing themselves, participated under the condition of not knowing their PRNP genotype. Due 
to the relatively small sample size and risk of de-identification, all raw study data involving 
human participants was made available to the editors and reviewers but will not be made 
available publicly. DNA sequences of gene blocks used for construction of humanized 
antibodies and human PrPC-AviTagTM are available at https://github.com/frontzekkarl/gPrD.  
  
Results 
Description of the cohort. We received blood samples and clinical information from a total 
of n = 241 individuals and selected n = 202 unmatched cases and controls for this analysis 
(figure 1). To test the robustness of our results, we matched n = 64 cases on n = 64 controls 
based on age (± 5 years), gender and blood storage conditions (i.e. serum / plasma, Table e-
2). Anti-PrPC autoantibody reactivity was measured by a sandwich enzyme-linked 
immunosorbent assay (ELISA), a description of the assay is provided in extended text and 
figures e-1 and e-2. Briefly, blood samples were diluted over a range of > 2 logs and bound 
autoantibodies were detected with anti-human IgG antibodies. Antibody titers are expressed 
as negative common logarithm of the half-maximal effective concentration (figure e-1E). Anti-
PrPC antibody reactivity was independent of serum IgG levels (Spearman’s ρ = 0.07, p = 0.69, 
figure 2A). The age of probands did not influence the IgG levels (Pearson r = 0.33, p = 0.16). 
To confirm our ability to detect human antibodies against specific targets, we tested a subset 
of individuals for the presence of IgG against the Epstein-Barr nuclear antigen (EBNA). 4/5 
PRNPWT and 16/16 PRNPMut individuals tested positive (corresponding to 95 % positive 
individuals), in line with anti-EBNA IgG seroprevalence in the general population (figure 2B) 
30.  
Prevalence of anti-PrPC autoantibodies in PRNP mutation carriers. The presence of 
coagulation factors (e.g. plasma instead of serum), and possibly age, but not female gender 
were associated with anti-PrPC autoantibody reactivity in bivariate and multivariate analyses 
(Table 2) 29.  We henceforth adjusted all analyses for age and presence of coagulation factors. 
Presence or absence of a pathogenic PRNP mutation was not associated with significant 
changes in anti-PrPC autoantibody reactivity (Table 3). Additionally, we matched both n = 62 
cases and controls on age (± 5 years), gender and blood sample type 26-28 (Table e-2). As with 
the unmatched cohort, PRNP mutation did not significantly influence anti-PrPC autoantibody 
titers in multivariate linear regression adjusted for matching factors (Table e-2). 
We then tested whether anti-PrPC autoantibody response was associated with symptoms of 
prion disease. Presence or absence of clinical signs was reported by n = 122 PRNP mutation 
carriers (out of a total of n = 124 enrolled): n = 76 (62.3 %) were asymptomatic carriers 
whereas n = 46 (37.7%) presented with clinically apparent disease. Detailed clinical data was 
available in n = 14 cases, the most common clinical presentations entailed cerebellar signs (n 
= 12, 85.7%) and dementia (n = 11, 78.6%). Status of 14-3-3 protein in cerebrospinal fluid, 
albeit a poor predictor of genetic prion disease 31, was provided by n = 121 of study 
participants. N = 17 individuals (all PRNP mutation carriers with clinically apparent disease) 
were tested with n = 8 (47.1%) being tested positive, in line with previous findings 31. Presence 
of prion-specific symptoms was not associated with alterations in anti-PrPC autoantibodies in 
an unmatched cohort (Table 3). This was confirmed in an analysis of a cohort consisting of n 
= 24 symptomatic PRNP mutation carriers and n = 24 asymptomatic PRNP mutation carriers 
matched on PRNP mutation, age and sample type (Table e-2). 
Post hoc subgroup analyses on the association of anti-PrPC autoantibodies with 
specific PrPC mutations, PrPC p.129 polymorphism and autoimmune disease and other 
immunological disorders. We analyzed the effects of PRNP mutations that were present at 
least five times in the study population, namely D178N and E200K, on anti-PrPC autoantibody 
titers: individuals with D178N mutations showed a significant trend towards lower autoantibody 
titers in bivariate analysis (Table 3). This finding, however, was not significant after adjusting 
for age and sample type (Table 3). E200K mutation carriers did not show significant changes 
in autoantibody reactivity (Table 3). The (M)ethionine/(V)aline polymorphism at codon 129 of 
the human PRNP gene was reported to affect the susceptibility to prion diseases 32. 
Information on p.129 polymorphism was available in n = 182 of study participants: n = 84 
(46.2%) were homozygous for methionine (p.129MM), n = 87 (47.8%) p.129MV, n = 11 (6.0%) 
p.129VV. None of the polymorphisms significantly altered autoantibody response to PrPC in a 
post hoc analysis (Table 4). In D178N carriers, the clinical phenotype was suggested to be 
dependent on the PRNP cis c.129 polymorphism: methionine was associated with FFI and 
valine with fCJD 2, although this association may not be universal 33, 34. In our cohort, n = 28 
patients could be unambiguously identified as D178N_cis129M and n = 5 patients as 
D178N_cis129V. No differences in mean antibody reactivity were seen between those two 
groups (Table 4).  
Co-occurrence of multiple autoimmune diseases is a commonly observed phenomenon 35. In 
order to test the influence of pre-existing autoimmune diseases on anti-PrPC autoantibody 
titers we searched clinical reports of study participants for presence of autoimmune disease 
and other immunological disorders. We were able to retrieve this information in n = 141 (69.8 
%) of cases: n = 8 individuals were diagnosed with autoimmune disease, namely Hashimoto’s 
thyroiditis (n = 3), Graves’ disease (n = 1), monoclonal gammopathy of unknown significance 
(n = 1), multiple sclerosis (n = 1), psoriasis (n = 1) and rheumatoid arthritis (n = 1). Multivariate 
linear regression analysis adjusted for age, gender and type of blood sample did not show a 
significant association of autoimmune disease with anti-PrPC autoantibody titers (Table 4). 
Temporal evolution of anti-PrPC autoantibodies. 44 individuals (21.8 %) donated blood 
multiple times, several months apart on which we performed a post hoc, time course analysis. 
PRNP wild-type individuals were observed over a longer time period compared to PRNP 
mutations carriers (17 ± 1.78 months vs. 10 ± 6.21 months, p = 1.42 x 10-5). PRNP mutation 
carriers showed larger variability in autoantibody titers, mean proportional change per year 
was, however, similar across groups (p = 0.23) and was overall negligible between two blood 
drawings (113.2 ± 61.44 % per year in PRNP mutation carriers versus 99.95 ± 17.22 % per 
year in PRNP wild-type individuals, figure 2C). None of the PRNP mutation carriers tested in 
this time course analysis exhibited clinical signs of prion disease.  
  
Discussion 
The diagnosis of a disease-associated PRNP mutation is a fateful and often devastating event 
for individuals carrying such mutations. The clinical penetrance of PRNP mutations can be 
very high, and no disease-modifying therapy is available as of today 2. Clinical signs of familial 
prion disease typically erupt in late adulthood although carriers arguably produce the mutated 
protein from the first day of their life 5. There are at least two scenarios that may account for 
this phenomenon: (1) the pathogenic mutations may slightly destabilize PrPC, thereby 
infinitesimally increasing the probability of pathological aggregation, or (2) the pathogenic 
conformation of PrPC is attained early on, but the body’s defenses stave off its consequences 
for many decades.  
In the case of scenario #1, extensive structural studies on pathogenic PrPC variants failed to 
reveal major structural alterations 20. We hypothesized that under scenario #2, the stochastic 
generation of PrPSc in mutation carriers might engender neoantigens, which in turn might lead 
to protective humoral responses. Remarkably, however, we found no evidence of induction of 
humoral antibody-mediated immunity against PrPC by pathogenic PRNP variants. Instead, our 
study suggests the prevalence of naturally occurring anti-PrPC antibodies in the general 
population independent of clinical signs of prion disease, PRNP variant or PRNP p.129 
polymorphism. Although reactivity to wild-type PrP has been reported in the serum of E219K 
homozygotes 10, and reactivity to a non-naturally-occurring PrP peptide was reported in 
commercial IgG 9, the present report is to our knowledge the first observation of the PRNP 
genotype-independent presence of autoantibodies to full-length, wild-type PrP in humans. 
Without disease-specific antibodies, one might speculate that PRNP mutations accumulate 
subclinical levels of prions to a point when clinical symptoms become evident.   
In a subset of individuals, anti-PrPC autoantibody reactivity was tested in multiple blood 
drawings up to 1.5 years apart: the mean change of autoantibody titers was similar across 
PRNP genotypes in line with previous reports that showed stable autoantibody levels at least 
over several years 36, 37.  
Matching in case-controls studies is a controversial topic 38. In our study, initial analyses were 
performed on unmatched cohorts adjusted for known confounders of blood autoantibody 
levels, this approach was described to increase statistical power 39. To strengthen our 
arguments, we compared anti-PrPC autoantibody levels in cases and matched controls, these 
results are in line with findings from the unmatched cohorts.  
An increasing number of autoantibodies against neurodegenerative targets are being explored 
as biomarkers and as potential therapeutics. Naturally occurring autoantibodies against 
hyperphosphorylated tau protein have been isolated from several asymptomatic blood donors 
40. Researchers from Neurimmune (Switzerland) recently reported the development of a fully 
human antibody against amyotrophic lateral sclerosis targeting pathologically misfolded 
SOD1, α-miSOD1, from a memory B-cell library from healthy elderly individuals 41. Phase III 
trials involving aducanumab, a bona fide human antibody with potent β-amyloid clearing 
capabilities, were, however, stopped prematurely 42.  
In previous works, we found that anti-PrPC antibodies can efficaciously counteract prions 6 – 
a finding which was later confirmed by several other researchers 43. We speculated that anti-
PrPC autoantibodies from the general population could represent a reservoir of potential 
therapeutic agents against prion diseases. We find, however, that the distribution of titers 
appears similar between mutation carriers and controls, and between symptomatic and pre-
symptomatic mutation carriers, arguing against the possibility that these autoantibodies are 
broadly beneficial. This is at variance with a previous, pre-clinical report claiming 
neuroprotective effects for naturally occurring antibodies to a PrP peptide 9. Similarly, naturally 
occurring anti-β-amyloid autoantibodies with neuroprotective effects were reported in mice, 
but did not meet primary cognitive endpoints when tested in a phase III clinical trial 44.  
Nonetheless, our work does not rule out the possibility of protective anti-PrP autoantibodies 
in the general population or in PRNP mutation carriers specifically. Our study was restricted 
to the assessment of autoantibody levels against full-length, wild-type, recombinant human 
PrPC . We did not evaluate the presence of antibodies specific to pathogenic PRNP mutations 
or to neoepitopes created by those mutations. Moreover, it is possible that humans develop 
antibodies specific to PrPSc, the aggregated form of the prion protein. In our experience such 
anti-PrPSc antibodies tend to cross-react, at least to some level, with PrPC 45. Another difficulty 
is that PrPSc structure is very heterogenous in genetic prion diseases: while brains from genetic 
CJD and sCJD patients show similar patterns of PrPSc, PrPSc is fragmented and of low 
molecular weight in brains from GSS patients and can show marked variation in individuals 
with the D178N mutation 2, 46.  Future studies will focus on the detection of rare, low-titer anti-
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Figure legends 
Figure 1. Flowchart of patient selection. Double line indicates cohorts selected for 
comparison of anti-PrPC autoantibody titers from individuals carrying wild-type or mutated 
PRNP alleles (right of double line) and cohort selected for comparing anti-PrPC autoantibody 
titers of symptomatic versus asymptomatic mutation carriers (left of double line). Blue boxes 
indicate matched cohorts.   
Figure 2. Correlation of anti-PrPC autoantibody reactivity with total IgG levels, IgG 
anti-EBV autoantibodies and change of autoantibody titers over time. 
(A) Correlation of total IgG with anti-PrPC autoantibody titers. (B) Qualitative assessment of 
anti-EBNA IgG antibodies in blood shows one PRNPWT individual without detectable anti-
EBNA IgG antibodies. Cut-off: ODabs=450nm (optical density at absorbance 𝜆=450 nm) = 0.2 
according to the manufacturer’s guidelines. (C) In two subsequent blood drawings, mean 
change of antibody titers per year is stable and similar between PRNP mutation and wild-
type carriers, but variance is larger in PRNP mutation carriers.  
  










p - Value 
Individuals enrolled, 
n 
124 78   
     
Age     
Mean (years) 49.3 42.8  0.004 




8 / 141 (5.7%) 61 (30.2 %)  
 
Female gender,  
n (%) 
80 (64.5 %) 37 (47.4 %)  0.02 
 
14-3-3 protein in 
CSF  
  80 (39.6 %) 2 n/a 
Test performed 
17 / 63  
(27.0 %) 




8 / 17 
(47.0 %) 
n/a   
 
Codon 129 
polymorphism, n (%) 
  20 (9.9 %) 3 < 0.0001 
Met / Met 
69 / 121 
(57.0 %) 
15 / 61 
 (24.6 %) 
  
Met / Val 
50 / 121 
(41.3 %) 
37 / 61 
(60.7 %) 
  
Val / Val 
2 / 121 
(1.7 %) 





mutation, n (%) 
    
P102L 3 (2.4 %) n/a   
D178N 37 (29.8 %) n/a   
E200K 77 (62.1 %) n/a   
V210I 2 (1.6 %) n/a   
Unique 4  5 (4.0 %) n/a   
 
Blood storage     
Plasma 98 (79.0 %) 70 (89.7 %)   
Serum 26 (21.0 %) 8 (10.3 %)   
1 due to few events of autoimmune disease, we pooled genotypes to eliminate possible 
identification. P-value compares numbers of individuals with or without autoimmune disease 
in PRNP mutation carriers and wild-type participants. 2 missing values: n = 61 PRNP 
mutation carriers, n = 19 PRNP wild-type. 3 missing values: n = 3 PRNP mutation carriers, n 
= 17 PRNP wild-type. 4 unique (n = 1) mutations: D178N/N171S, V180I, T183A, F198S, 
E200G.  
Table 2. Age and lack of coagulation factors in blood (e.g. serum probes), but not 
gender, are significantly associated with anti-PrPC autoantibody reactivity. Due to lack 
of confounding effects of gender in multivariate model B, all further analyses were adjusted 
for blood sample type (serum/plasma) and age. 
Bivariate analyses 
Risk factor β coefficient 95% confidence interval p-Value 
Age 0.990 0.982 - 0.998 0.05 * 
Female gender 1.14 0.86 - 1.48 0.42 
Plasma instead 
of serum 
1.84 1.31 - 2.58 0.004 * 
Multivariate Analysis - model A 
Age 0.990 0.982 - 0.997  0.032 * 
Plasma instead 
of serum 
1.88 1.34 - 2.63 0.002 * 
Multivariate Analysis - model B 
Age 0.989 0.981 - 0.997 0.026 * 
Female gender 1.16 0.90 - 1.50 0.35 
Plasma instead 
of serum 
1.86 1.33 - 2.61 0.003 * 
 
  
Table 3. Impact of PRNP mutation status on anti-PrPC autoantibody reactivity.  
Risk factor β coefficient 95% confidence interval p-Value 
PRNP mutation (all)    
crude 0.81 0.62 - 1.05 0.19 
adjusted 0.92 0.70 - 1.20 0.61 
PRNP D178N 
mutation 
   
crude 0.61 0.44 - 0.86 0.02 * 
adjusted 0.75 0.53 - 1.06 0.17 
PRNP E200K 
mutation 
   
crude 1.16 0.89 - 1.16 0.36 
adjusted 1.18 0.91 - 1.54 0.30 
 
Clinical signs of 
prion disease 
   
crude 0.90 0.59 - 1.38 0.64 
adjusted 0.94 0.61 - 1.46 0.79 
 
  
Table 4. Impact of PRNP codon 129 polymorphism and history of autoimmune disease 
on anti-PrPC autoantibody reactivity.  
Risk factor β coefficient 95% confidence interval p-Value 
p.129MM    
crude 0.83 0.63 - 1.10 0.28 
adjusted 0.88 0.67 - 1.15 0.43 
p.129MV    
crude 1.23 0.94 - 1.62 0.21 
adjusted 1.13 0.86 - 1.48 0.46 
p.129VV    
crude 0.88 0.49 - 1.56 0.71 
adjusted 1.04 0.59 - 1.83 0.90 
 
D178N / cis-129M    
crude 1.18 0.44 - 3.15 0.78 





   
crude 0.96 0.47 - 1.96 0.92 
adjusted 1.12 0.55 - 2.26 0.76 
 
 
